Skip to main content
Top
Published in: Supportive Care in Cancer 4/2008

01-04-2008 | Supportive Care International

Use of chemotherapy at the end of life in a Portuguese oncology center

Authors: José Ferraz Gonçalves, Carmen Goyanes

Published in: Supportive Care in Cancer | Issue 4/2008

Login to get access

Abstract

Goals of work

Chemotherapy plays a major role in the treatment of cancer. However, it is sometimes thought of as being taken too far, being used in many cases close to death. The purpose of this study is to determine the proximity of chemotherapy use to the patient’s death in our hospital.

Materials and methods

This study comprised the analysis of the charts of 1,064 patients aged over 16 years with solid tumors who died in 2002 and were treated at the Porto Section of the Portuguese Institute of Oncology.

Main results

Four hundred ten of the 1,064 patients (39%) underwent chemotherapy. Fifty-two percent of those that underwent chemotherapy did so in the last 6 months of their lives, 31% in the last 3 months, 13% in the last month, and 3% in the last week. In the context of the total cohort of 1,064, the percentages of those that underwent chemotherapy was 20, 12, 5, and 1%, respectively. By multivariate analysis, age <65 years, breast and lung cancers, and metastases were positively associated with chemotherapy; kidney cancer and comorbidity were associated with a lower probability of undergoing chemotherapy. Three hundred sixty-one patients (34%) were admitted to the palliative care unit of the hospital.

Conclusion

It was concluded that in this hospital, chemotherapy is not used as close to death as often as most professionals feel and the literature reports. There are various possible explanations for this discrepancy; one of them may be the influence of health care systems. It would be useful to see what is happening in other countries with different health care systems.
Literature
1.
go back to reference Aragon-Ching JB, Cohn JB, Cohn A (2003) Chemotherapy at the end of life. Proc Am Soc Clin Oncol 22(abst 3119) Aragon-Ching JB, Cohn JB, Cohn A (2003) Chemotherapy at the end of life. Proc Am Soc Clin Oncol 22(abst 3119)
2.
go back to reference Emanuel EJ, Young-Xu Y, Levinsky NG, Gazelle G, Saynina O, Ash AS (2003) Chemotherapy use among Medicaire beneficiaries at the end of life. Ann Intern Med 138:639–643PubMed Emanuel EJ, Young-Xu Y, Levinsky NG, Gazelle G, Saynina O, Ash AS (2003) Chemotherapy use among Medicaire beneficiaries at the end of life. Ann Intern Med 138:639–643PubMed
3.
go back to reference Earle CC, Neville BA, Landrum MB, Ayanian JZ, Block SD, Weeks JC (2004) Trends in the aggressiveness of cancer care near the end of life. J Clin Oncol 22:315–321PubMedCrossRef Earle CC, Neville BA, Landrum MB, Ayanian JZ, Block SD, Weeks JC (2004) Trends in the aggressiveness of cancer care near the end of life. J Clin Oncol 22:315–321PubMedCrossRef
4.
go back to reference Matsuyama R, Reddy S, Smith TJ (2006) Why do patients choose chemotherapy near the end of life? A review of the perspective of those facing death from cancer. J Clin Oncol 24:3490–3496PubMedCrossRef Matsuyama R, Reddy S, Smith TJ (2006) Why do patients choose chemotherapy near the end of life? A review of the perspective of those facing death from cancer. J Clin Oncol 24:3490–3496PubMedCrossRef
5.
go back to reference Earle CC, Venditti LN, Neumann PJ, Gelber RD, Weinstein MC, Potosky AL, Weeks JC (2000) Who gets chemotherapy for metastatic lung cancer. Chest 117:1239–1246PubMedCrossRef Earle CC, Venditti LN, Neumann PJ, Gelber RD, Weinstein MC, Potosky AL, Weeks JC (2000) Who gets chemotherapy for metastatic lung cancer. Chest 117:1239–1246PubMedCrossRef
6.
go back to reference Harlan LC, Clegg LX, Trimble EL (2003) Trends in surgery and chemotherapy for women diagnosed with ovarian cancer in the United States. J Clin Oncol 21:3488–3494PubMedCrossRef Harlan LC, Clegg LX, Trimble EL (2003) Trends in surgery and chemotherapy for women diagnosed with ovarian cancer in the United States. J Clin Oncol 21:3488–3494PubMedCrossRef
7.
go back to reference Hurria A, Naeim A, Elkin E, Limaye S, Grover A, Hudis C, Pearce C, Robson M (2007) Adjuvant treatment recommendations in older women with breast cancer: a survey of oncologists. Crit Rev Oncol Hematol 61:255–260PubMedCrossRef Hurria A, Naeim A, Elkin E, Limaye S, Grover A, Hudis C, Pearce C, Robson M (2007) Adjuvant treatment recommendations in older women with breast cancer: a survey of oncologists. Crit Rev Oncol Hematol 61:255–260PubMedCrossRef
8.
go back to reference Doyle C, Crump M, Pintilie M, Oza AM (2001) Does palliative chemotherapy palliate? Evaluation of expectations, outcomes, and costs in women receiving chemotherapy for advanced ovarian cancer. J Clin Oncol 19:1266–1274PubMed Doyle C, Crump M, Pintilie M, Oza AM (2001) Does palliative chemotherapy palliate? Evaluation of expectations, outcomes, and costs in women receiving chemotherapy for advanced ovarian cancer. J Clin Oncol 19:1266–1274PubMed
9.
go back to reference Slevin ML, Stubbs I, Plant HJ et al (1990) Attitudes to chemotherapy: comparative views of patients with cancer with those of doctors, nurses, and general public. BMJ 300:1458–1460PubMedCrossRef Slevin ML, Stubbs I, Plant HJ et al (1990) Attitudes to chemotherapy: comparative views of patients with cancer with those of doctors, nurses, and general public. BMJ 300:1458–1460PubMedCrossRef
10.
go back to reference Yellen SB, Cella DF (1995) Someone to live for: social well-being, parenthood status and decision-making in oncology. J Clin Oncol 13:1255–1264PubMed Yellen SB, Cella DF (1995) Someone to live for: social well-being, parenthood status and decision-making in oncology. J Clin Oncol 13:1255–1264PubMed
11.
go back to reference Jirillo A, Boscaro M, Passeto LM, Monfardini S (2005) Chemotherapy at the end of life: an open question. Tumori 91:104–105PubMed Jirillo A, Boscaro M, Passeto LM, Monfardini S (2005) Chemotherapy at the end of life: an open question. Tumori 91:104–105PubMed
12.
go back to reference Glare P, Virik K, Jones M et al (2003) A systematic review of physicians’ predictions in terminally ill cancer patients. BMJ 327:195–200PubMedCrossRef Glare P, Virik K, Jones M et al (2003) A systematic review of physicians’ predictions in terminally ill cancer patients. BMJ 327:195–200PubMedCrossRef
13.
go back to reference Ellis PA, Smith IE, Hardy JR, Nicolson MC, Talbot DC, Ashley SE, Priest K (1995) Symptom relief with MVPP (mitomycin C, vinblastine and cisplatina) chemotherapy in advanced non-small-cell lung cancer. BJC 71:366–370PubMed Ellis PA, Smith IE, Hardy JR, Nicolson MC, Talbot DC, Ashley SE, Priest K (1995) Symptom relief with MVPP (mitomycin C, vinblastine and cisplatina) chemotherapy in advanced non-small-cell lung cancer. BJC 71:366–370PubMed
14.
go back to reference Cullen MH, Billingham LJ, Woodroffe CM et al (1999) Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life. J Clin Oncol 17:3188–3194PubMed Cullen MH, Billingham LJ, Woodroffe CM et al (1999) Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life. J Clin Oncol 17:3188–3194PubMed
15.
go back to reference Cunningham D, Pyrhönen S, James RD et al (1998) Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 352:1413–1418PubMedCrossRef Cunningham D, Pyrhönen S, James RD et al (1998) Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 352:1413–1418PubMedCrossRef
16.
go back to reference Burris HA, Moore MJ, Andersen MJ et al (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15:2403–2413PubMed Burris HA, Moore MJ, Andersen MJ et al (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15:2403–2413PubMed
17.
go back to reference Wan GJ, Counte MA, Cella DF (1997) The influence of personal expectations on cancer patients’ report of health-related quality of life. Psycho-Oncol 6:1–11CrossRef Wan GJ, Counte MA, Cella DF (1997) The influence of personal expectations on cancer patients’ report of health-related quality of life. Psycho-Oncol 6:1–11CrossRef
18.
go back to reference Graffar M (1956) Une méthode de Classification Social d’échantillon de la population. Courier 6:455–459 Graffar M (1956) Une méthode de Classification Social d’échantillon de la population. Courier 6:455–459
Metadata
Title
Use of chemotherapy at the end of life in a Portuguese oncology center
Authors
José Ferraz Gonçalves
Carmen Goyanes
Publication date
01-04-2008
Publisher
Springer-Verlag
Published in
Supportive Care in Cancer / Issue 4/2008
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-007-0316-x

Other articles of this Issue 4/2008

Supportive Care in Cancer 4/2008 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine